HuR expression is a marker of poor prognosis in renal cell carcinoma

Tumor Biology

Volumn 32, Issue 3, 2011, Pages 481-487

  Ronkainen, Hanna ^a   Vaarala, Markku H ^a   Hirvikoski, Pasi ^a   Ristimäki, Ari ^a,b  

^a OULU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

COX 2; HuR; Immunohistochemistry; Prognosis; Surgery; Survival

Indexed keywords

BIOLOGICAL MARKER; CYCLOOXYGENASE 2; HUR PROTEIN; SMALL INTERFERING RNA; ELAV-LIKE PROTEIN 1; MEMBRANE ANTIGEN; PTGS2 PROTEIN, HUMAN; RNA BINDING PROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER MORPHOLOGY; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CELL NUCLEUS; CONTROLLED STUDY; CYTOPLASM; ENZYME LOCALIZATION; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SURVIVAL TIME; CHEMISTRY; KIDNEY TUMOR; MIDDLE AGED; MORTALITY; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, SURFACE; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CYCLOOXYGENASE 2; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; RNA-BINDING PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 79960604307     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-010-0141-6     Document Type: Article

References (37)

1. Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J Urol. 2001;166:1611-23.
2. Breda A, Konijeti R, Lam JS. Patterns of recurrence and surveillance strategies for renal cell carcinoma following surgical resection. Expert Rev Anticancer Ther. 2007;7:847-62. (Pubitemid 47007991)
3. Phuoc NB, Ehara H, Gotoh T, Nakano M, Kamei S, Deguchi T, et al. Prognostic value of the co-expression of carbonic anhydrase IX and vascular endothelial growth factor in patients with clear cell renal cell carcinoma. Oncol Rep. 2008;20:525-30.
4. McGuire BB, Fitzpatrick JM. Biomarkers in renal cell carcinoma. Curr Opin Urol. 2009;19:441-6.
5. Ma WJ, Cheng S, Campbell C, Wright A, Furneaux H. Cloning and characterization of HuR, a ubiquitously expressed elav-like protein. J Biol Chem. 1996;271:8144-51. (Pubitemid 26108641)
6. Fan XC, Steitz JA. Overexpression of HuR, a nuclear-cytoplasmic shuttling protein, increases the in vivo stability of ARE-containing mRNAs. EMBO J. 1998;17:3448-60. (Pubitemid 28279517)
7. Brennan CM, Steitz JA. HuR and mRNA stability. Cell Mol Life Sci. 2001;58:266-77. (Pubitemid 32217358)
8. Abdelmohsen K, Gorospe M. Posttranscriptional regulation of cancer traits by HuR. Wiley Interdisciplinary Reviews-RNA; 2010. doi:10.1002/wrna.4.
9. Erkinheimo TL, Lassus H, Sivula A, Sengupta S, Furneaux H, Hla T, et al. Cytoplasmic HuR expression correlates with poor outcome and with cyclooxygenase 2 expression in serous ovarian carcinoma. Cancer Res. 2003;63:7591-4. (Pubitemid 37466678)
10. Denkert C, Weichert W, Pest S, Koch I, Licht D, Kobel M, et al. Overexpression of the embryonic-lethal abnormal vision-like protein HuR in ovarian carcinoma is a prognostic factor and is associated with increased cyclooxygenase 2 expression. Cancer Res. 2004;64:189-95. (Pubitemid 38114097)
11. Mrena J, Wiksten JP, Thiel A, Kokkola A, Pohjola L, Lundin J, et al. Cyclooxygenase-2 is an independent prognostic factor in gastric cancer and its expression is regulated by the messenger RNA stability factor HuR. Clin Cancer Res. 2005;11:7362-8. (Pubitemid 41507695)
12. Heinonen M, Bono P, Narko K, Chang SH, Lundin J, Joensuu H, et al. Cytoplasmic HuR expression is a prognostic factor in invasive ductal breast carcinoma. Cancer Res. 2005;65:2157-61. (Pubitemid 40490122)
13. Dixon DA, Tolley ND, King PH, Nabors LB, McIntyre TM, Zimmerman GA, et al. Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells. J Clin Invest. 2001;108:1657-65. (Pubitemid 33144876)
14. Menter DG, Schilsky RL, DuBois RN. Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward. Clin Cancer Res. 2010;16:1384-90.
15. Miyata Y, Koga S, Kanda S, Nishikido M, Hayashi T, Kanetake H. Expression of cyclooxygenase-2 in renal cell carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, expression of matrix metalloproteinase-2, and survival. Clin Cancer Res. 2003;9:1741-9. (Pubitemid 36554599)
16. Ronkainen H, Kauppila S, Hirvikoski P, Vaarala MH. Evaluation of myosin VI, E-cadherin and beta-catenin immunostaining in renal cell carcinoma. J Exp Clin Cancer Res. 2010;29:2.
17. UICC. TNM classification of malignant tumours. 6th ed. New York: Wiley; 2002
18. IARC. Tumours of the urinary system and male genital organs. Lyon: IARC; 2004.
19. Sefton BM. Labeling cultured cells with 32Pi and preparing cell lysates for immunoprecipitation. In: Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA, Struhl K, editors. Current Protocols in Molecular Biology. London: Wiley; 2005. Unit 18.2.
20. Danilin S, Sourbier C, Thomas L, Rothhut S, Lindner V, Helwig JJ, et al. Von hippel-lindau tumor suppressor gene-dependent mRNA stabilization of the survival factor parathyroid hormone-related protein in human renal cell carcinoma by the RNA-binding protein HuR. Carcinogenesis. 2009;30:387-96.
21. Danilin S, Sourbier C, Thomas L, Lindner V, Rothhut S, Dormoy V, et al. Role of the RNA-binding protein HuR in human renal cell carcinoma. Carcinogenesis. 2010;31:1018-26.
22. Sengupta S, Jang BC, Wu MT, Paik JH, Furneaux H, Hla T. The RNA-binding protein HuR regulates the expression of cyclooxygenase-2. J Biol Chem. 2003;278:25227-33. (Pubitemid 37548687)
23. Hashimoto Y, Kondo Y, Kimura G, Matsuzawa I, Sato S, Ishizaki M, et al. Cyclooxygenase-2 expression and relationship to tumour progression in human renal cell carcinoma. Histopathology. 2004;44:353-9. (Pubitemid 38491302)
24. Tuna B, Yorukoglu K, Gurel D, Mungan U, Kirkali Z. Significance of COX-2 expression in human renal cell carcinoma. Urology. 2004;64:1116-20. (Pubitemid 39647051)
25. Sozen S, Gurocak S, Erdem O, Acar C, Kordan Y, Akyol G, et al. Cyclooxygenase-2 expression: does it have a probable role in tumorigenesis mechanisms of renal cell carcinoma? Int Urol Nephrol. 2008;40:295-301.
26. Lopez de Silanes I, Lal A, Gorospe M. HuR: post-transcriptional paths to malignancy. RNA Biol. 2005;2:11-3.
27. Yoo PS, Sullivan CA, Kiang S, Gao W, Uchio EM, Chung GG, et al. Tissue microarray analysis of 560 patients with colorectal adenocarcinoma: high expression of HuR predicts poor survival. Ann Surg Oncol. 2009;16:200-7.
28. Yi X, Zhou Y, Zheng W, Chambers SK. HuR expression in the nucleus correlates with high histological grade and poor disease-free survival in ovarian cancer. Aust N Z J Obstet Gynaecol. 2009;49:93-8.
29. Niesporek S, Kristiansen G, Thoma A, Weichert W, Noske A, Buckendahl AC, et al. Expression of the ELAV-like protein HuR in human prostate carcinoma is an indicator of disease relapse and linked to COX-2 expression. Int J Oncol. 2008;32:341-7. (Pubitemid 351188300)
30. Iwamura M, Wu W, Muramoto M, Ohori M, Egawa S, Uchida T, et al. Parathyroid hormone-related protein is an independent prognostic factor for renal cell carcinoma. Cancer. 1999;86:1028-34. (Pubitemid 29439858)
31. Massfelder T, Lang H, Schordan E, Lindner V, Rothhut S, Welsch S, et al. Parathyroid hormone-related protein is an essential growth factor for human clear cell renal carcinoma and a target for the von hippel-lindau tumor suppressor gene. Cancer Res. 2004;64:180-8. (Pubitemid 38114096)
32. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989;246:1306-9. (Pubitemid 20066716)
33. Datta K, Mondal S, Sinha S, Li J, Wang E, Knebelmann B, et al. Role of elongin-binding domain of von hippel lindau gene product on HuR-mediated VPF/VEGF mRNA stability in renal cell carcinoma. Oncogene. 2005;24:7850-8. (Pubitemid 41715191)
34. Levy NS, Chung S, Furneaux H, Levy AP. Hypoxic stabilization of vascular endothelial growth factor mRNA by the RNA-binding protein HuR. J Biol Chem. 1998;273:6417-23. (Pubitemid 28144735)
35. Galban S, Martindale JL, Mazan-Mamczarz K, Lopez de Silanes I, Fan J, Wang W, et al. Influence of the RNA-binding protein HuR in pVHL-regulated p53 expression in renal carcinoma cells. Mol Cell Biol. 2003;23:7083-95. (Pubitemid 37210992)
36. Yuen JS, Cockman ME, Sullivan M, Protheroe A, Turner GD, Roberts IS, et al. The VHL tumor suppressor inhibits expression of the IGF1R and its loss induces IGF1R upregulation in human clear cell renal carcinoma. Oncogene. 2007;26:6499-508. (Pubitemid 47530598)
37. Parker AS, Cheville JC, Janney CA, Cerhan JR. High expression levels of insulin-like growth factor-I receptor predict poor survival among women with clear-cell renal cell carcinomas. Hum Pathol. 2002;33:801-5. (Pubitemid 34983100)